Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
In this study, the efficacy of nilotinib at 400 mg BID will be compared with imatinib at 400
mg BID in suboptimal molecular response patients. To determine study eligibility, suboptimal
molecular response will be defined as patients who have achieved a complete cytogenetic
response (CCyR) but have not achieved a MMR, after at least 18 months of treatment on first
line imatinib therapy at a minimum dose of 400mg daily (Baccarani 2006).